Loading
Life sciences · Journal article
Metabolism Open · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity induces catecholamine resistance in adipose tissue, which impairs lipolysis and reduces energy expenditure. Here, we show that phillyrin attenuates catecholamine resistance in obese adipose tissue in association with suppression of the IL-6R–STAT3–ERK1/2 positive feedback loop. In high-fat diet (HFD)-induced obese mice, low-dose phillyrin (1 mg/kg) significantly elevated 24-h energy expenditure and oxygen consumption. It also markedly enhanced β3-adrenergic-stimulated lipolysis in both visceral and subcutaneous adipose depots, accompanied by increased phosphorylation of hormone-sensitive lipase (HSL) at Ser660. Furthermore, phillyrin effectively rescued IL-6-induced catecholamine resistance both in vitro and in vivo. Mechanistically, phillyrin downregulated IL-6Rα expression and suppressed the phosphorylation of STAT3 (Tyr705) and ERK1/2, consistent with attenuation of the self-amplifying inflammatory loop that desensitizes β-adrenergic signaling. These findings implicate the IL-6R–STAT3–ERK1/2 positive feedback loop as a mediator of obesity-associated catecholamine resistance and support phillyrin as a promising therapeutic candidate for improving lipolytic capacity and metabolic homeostasis in obesity.